Search

Your search keyword '"Pisters, Peter"' showing total 967 results
Start Over Author "Pisters, Peter"
967 results on '"Pisters, Peter"'

152. Extraosseous Osteosarcoma: Response to Treatment and Long-Term Outcome

Author

Ahmad, Syed A., Patel, Shreyaskumar R., Ballo, Matthew T., Baker, Treneth P., Yasko, Alan W., Wang, Xuemei, Feig, Barry W., Hunt, Kelly K., Lin, Patrick P., Weber, Kristen L., Chen, Lei L., Zagars, Gunar K., Pollock, Raphael E., Benjamin, Robert S., and Pisters, Peter W.T.

Published
2002

155. Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas

Author

Meric, Funda, Hess, Kenneth R., Varma, Datla G. K., Hunt, Kelly K., Pisters, Peter W. T., Milas, Kresimira M., Patel, Shreyaskumar R., Benjamin, Robert S., Plager, Carl, Papadopoulos, Nickolas E. J., Burgess, Michael A., Pollock, Raphael E., and Feig, Barry W.

Subjects
Cancer -- Research, Radiography, Medical -- Physiological aspects, Chemotherapy -- Evaluation, Sarcoma, Cancer survivors -- Health aspects, Health
Published
2002

157. Adult rhabdomyosarcoma

Author

Little, Darren J., Ballo, Matthew T., Zagars, Gunar K., Pisters, Peter W. T., Patel, Shreyaskumar R., El-Naggar, Adel K., Garden, Adam S., and Benjamin, Robert S.

Subjects
Cancer -- Demographic aspects, Rhabdomyosarcoma, Electron beams -- Health aspects, Chemotherapy -- Health aspects, Health
Published
2002

158. Tumor volume as a prognostic factor for sarcomatosis

Author

Bilimoria, Malcolm M., Holtz, Daniel J., Mirza, Nadeem Q., Feig, Barry W., Pisters, Peter W. T., Patel, Shreyaskumar, Pollock, Raphael E., Benjamin, Robert S., Papadopoulos, Nicholas E., Plager, Carl, Murphy, Anne, Griffin, Janet R., Burgess, Michael A., and Hunt, Kelly K.

Subjects
Cancer -- Research, Medical research -- Analysis, Sarcoma, Patients -- Demographic aspects, Cancer survivors -- Statistics, Health, University of Texas -- Research
Published
2002

171. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction

Author

Ajani, Jaffer A., Komaki, Ritsuko, Putnam, Joe B., Walsh, Garrett, Nesbitt, Jon, Pisters, Peter W., Lynch, Patrick M., Vaporciyan, Ara, Smythe, Roy, Lahoti, Sandeep, Raijman, Issac, Swisher, Stephen, Martin, Faye D., and Roth, Jack A.

Subjects
Esophageal cancer -- Care and treatment, Stomach cancer -- Care and treatment, Health
Published
2001

179. Primary treatment of cystosarcoma phyllodes of the breast

Author

Chaney, Arthur W., Pollack, Alan, Mcneese, Marsha D., Zagars, Gunar K., Pisters, Peter W.T., Pollock, Raphael E., and Hunt, Kelly K.

Subjects
Breast cancer -- Care and treatment, Sarcoma -- Care and treatment, Health
Published
2000

182. Reoperative pancreaticoduodenectomy for periampullary carcinoma

Author

Robinson, Emily K., Lee, Jeffrey E., Lowy, Andrew M., Fenoglio, Claudia J., Pisters, Peter W.T., and Evans, Douglas B.

Subjects
Perineum, Pancreatectomy -- Usage, Duodenum, Reoperation -- Case studies, Health
Abstract

BACKGROUND: We have noted a continued increase in the number of patients referred to our institution for presumed or biopsy-proven periampullary carcinoma following an 'exploratory' laparotomy during which tumor resection was not performed. Although previous work has demonstrated the safety of reoperative pancreaticoduodenectomy (PD), the need to avoid nontherapeutic laparotomy in these patients is obvious. In the current study, we sought to determine why PD was not performed at the initial operation. METHODS: Using the prospective pancreatic cancer database, we identified all patients who underwent reoperative PD at our institution between June 1990 and October 1995. Radiologic imaging prior to reoperation was standardized and based on thin-section, contrast-enhanced computed tomography (CT); helical CT was used in more recent cases. Pathologic data were obtained, and initial outside operative reports were reviewed to determine why a PD was not performed at the initial procedure. RESULTS: Twenty-nine patients underwent reoperative PD. Resection was not performed at the initial laparotomy because of the surgeon's assessment of local unresectability (17 patients), lack of a tissue diagnosis of malignancy (9), misdiagnoses (2), and error in intraoperative management (1). In the 17 patients deemed to have unresectable disease, successful reoperative PD required vascular resection in 10. All 10 of these patients had resection with negative microscopic margins of excision. Of the 9 patients who did not have resection owing to diagnostic uncertainty, all 9 had undergone multiple intraoperative biopsies interpreted as negative for malignancy; 6 of 9 had carcinoma confirmed on permanent-section analysis of the biopsy specimens. Four patients suffered major complications from intraoperative large-needle biopsy. CONCLUSIONS: Detailed preoperative imaging and a clearly defined operative plan would have allowed successful resection at the initial operation in 27 of 29 patients who underwent reoperative PD. Avoidable patient morbidity and the cost of unnecessary surgery argue strongly against 'exploratory' surgery in patients with presumed periampullary neoplasms.

Published
1996

193. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience

Author

Cloyd, Jordan M., primary, Katz, Matthew H. G., additional, Prakash, Laura, additional, Varadhachary, Gauri R., additional, Wolff, Robert A., additional, Shroff, Rachna T., additional, Javle, Milind, additional, Fogelman, David, additional, Overman, Michael, additional, Crane, Christopher H., additional, Koay, Eugene J., additional, Das, Prajnan, additional, Krishnan, Sunil, additional, Minsky, Bruce D., additional, Lee, Jeffrey H., additional, Bhutani, Manoop S., additional, Weston, Brian, additional, Ross, William, additional, Bhosale, Priya, additional, Tamm, Eric P., additional, Wang, Huamin, additional, Maitra, Anirban, additional, Kim, Michael P., additional, Aloia, Thomas A., additional, Vauthey, Jean-Nicholas, additional, Fleming, Jason B., additional, Abbruzzese, James L., additional, Pisters, Peter W. T., additional, Evans, Douglas B., additional, and Lee, Jeffrey E., additional

Published
2016
Full Text
View/download PDF

196. Loss of PTEN Expression Is Associated with Recurrence and Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma

Author

Foo, Wai Chin, Rashid, Asif, Wang, Hua, Katz, Matthew H., Lee, Jeffrey E, Pisters, Peter W, Wolff, Robert A., Abbruzzese, James L., Fleming, Jason B, and Wang, Huamin

Subjects
Adult, Aged, 80 and over, Male, PTEN Phosphohydrolase, Kaplan-Meier Estimate, Middle Aged, Prognosis, Immunohistochemistry, Article, Pancreatic Neoplasms, Young Adult, Tissue Array Analysis, Biomarkers, Tumor, Humans, Female, Neoplasm Recurrence, Local, Aged, Carcinoma, Pancreatic Ductal
Abstract

Phosphatase and tensin homolog (PTEN) is a tumor suppressor in the AKT/mTOR pathway. Animal model studies have shown that loss of PTEN function is involved in the progression of pancreatic cancer. However, the prognostic significance of loss of PTEN expression in pancreatic cancer is unclear. PTEN expression was evaluated by immunohistochemistry on tissue microarrays consisting of multiple cores of 133 resected stage II pancreatic ductal adenocarcinomas. A PTEN expression score was calculated as the product of the percentage of positive tumor cells and the intensity of PTEN staining. We categorized PTEN expression for each tumor as retained (PTEN score5) or lost (PTEN score ≤5). Thirty-four (25.6%) patients had tumors with loss of PTEN expression, and 99 (74.4%) had tumors with retained PTEN expression. Recurrence/Metastasis was observed in 88.2% (30/34) of patients whose tumors showed loss of PTEN compared with 68.7% (68/99) of patients whose tumors showed retained PTEN (P = .03). Patients whose tumors showed loss of PTEN had a shorter overall survival (median, 19.9 ± 3.6 months) than did patients whose tumors had retained PTEN (32.7 ± 5.0 months, P = .03). In a multivariate analysis, loss of PTEN expression was an independent prognostic factor for poor overall survival in patients with stage II pancreatic ductal adenocarcinoma. No significant correlations between loss of PTEN expression and other clinicopathologic parameters were observed (P.05). Assessment of PTEN expression may be used as a prognostic marker for patients with resected pancreatic ductal adenocarcinoma.

Published
2012

198. Histologic Tumor Involvement of Superior Mesenteric Vein/Portal Vein Predicts Poor Prognosis in Patients with Stage II Pancreatic Adenocarcinoma Treated with Neoadjuvant Chemoradiation

Author

Wang, Jiansheng, Estrella, Jeannelyn S., Peng, Lan, Rashid, Asif, Varadhachary, Gauri R., Wang, Hua, Lee, Jeffrey E, Pisters, Peter W T, Vauthey, Jean-Nicolas, Katz, Matthew H., Gomez, Henry F., Evans, Douglas B., Abbruzzese, James L., Fleming, Jason B, and Wang, Huamin

Subjects
Adult, Aged, 80 and over, Male, Portal Vein, Chemoradiotherapy, Adenocarcinoma, Middle Aged, Prognosis, Survival Analysis, Article, Disease-Free Survival, Neoadjuvant Therapy, Pancreatic Neoplasms, Mesenteric Artery, Superior, Humans, Female, Neoplasm Invasiveness, Aged
Abstract

Studies have shown that superior mesenteric vein (SMV)/portal vein (PV) resection with pancreaticoduodenectomy (PD) is safe and feasible for patient with pancreatic adenocarcinoma (PAC). However, the prognostic significance of tumor involvement of the resected vein in patients who received neoadjuvant therapy is unclear.The authors evaluated 225 consecutive patients with stage II PAC who received neoadjuvant therapy and PD with or without SMV/PV resection. The resected SMV/PV was entirely submitted for histologic assessment and reviewed in all cases. Tumor involvement of the SMV/PV was correlated with clinicopathologic features and survival.Among the 225 patients, SMV/PV resection was performed in 85 patients. Histologic tumor involvement of the resected SMV/PV was identified in 57 patients. Histologic tumor involvement of the SMV/PV was associated with larger tumor size, higher rates of positive margin, and local/distant recurrence. By multivariate analysis, tumor involvement of the SMV/PV was an independent predictor of both disease-free survival (DFS) and overall survival (OS). However, addition of venous resection to PD itself had no impact on either DFS or OS compared with those with PD alone.Histologic tumor involvement of the SMV/PV is an independent predictor of both DFS and OS in patients with stage II PAC treated with neoadjuvant therapy and PD. Complete histologic evaluation of the resected SMV/PV is important for the prognosis in patients with PAC who received neoadjuvant therapy and PD.

Published
2011

199. Superior Mesenteric Artery Margin of Posttherapy Pancreaticoduodenectomy and Prognosis in Patients With Pancreatic Ductal Adenocarcinoma

Author

Liu, Li, primary, Katz, Matthew H., additional, Lee, Sun M., additional, Fischer, Laurice K., additional, Prakash, Laura, additional, Parker, Nathan, additional, Wang, Hua, additional, Varadhachary, Gauri R., additional, Wolff, Robert A., additional, Lee, Jeffrey E., additional, Pisters, Peter W., additional, Maitra, Anirban, additional, Fleming, Jason B., additional, Estrella, Jeannelyn, additional, Rashid, Asif, additional, and Wang, Huamin, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results